OR

Browse By

Engineering Cyclic Peptides For Oral Bioavailability (2015–2017)

Abstract:
The 21st century has become the age of injectable peptide therapeutics. To fully realise their benefits, peptide drugs need to become smaller, cheaper and orally deliverable. Proteins often exhibit their potent and selective biological actions through small peptide surfaces. These surfaces have been mimicked in cyclic peptides that are similarly potent and selective. However, they do not have the right properties to be oral drugs. This project aims to rectify their deficiencies by re-engineering their surfaces to survive degradation in the gut, permeate membranes and withstand clearance from blood. Outcomes will be new information and technology for downsizing proteins to small orally bioavailable peptides for therapeutic applications.
Grant type:
ARC Discovery Projects
Researchers:

  • Professor David Fairlie

    NHMRC Leadership Fellow and Group L
    Institute for Molecular Bioscience
    NHMRC Leadership Fellow and Group L
    Institute for Molecular Bioscience
    Affiliate of ARC COE for Innovation
    ARC Centre of Excellence for Innovations in Peptide and Protein Science
    Institute for Molecular Bioscience
    of Institute for Molecular Bioscien
    Institute for Molecular Bioscience
Funded by:
Australian Research Council